Company intelligence / Profile preview

AIVF

Ownership: Private
Employees: ~75
Development stage: Other

Overview

AIVF has developed the EMA platform—an AI-driven system that evaluates embryo viability from fertilization through Day 5/6 to predict implantation success. Clinical data show a ~70% probability of successful pregnancy with high EMA scores and a >27% reduction in cycles needed to reach fetal heartbeat. The company also launched the first non-invasive AI-based euploidy screening using time-lapse videos. Their solutions are CE marked and used globally.

Therapeutic areas: Women's Health
Modalities: Device (AI-powered software platform)Non-pharmacological therapy (digital decision support for IVF)Diagnostic device (AI-based embryo assessment and genetic screening)
Industry: Digital Health Medical Devices

Partnerships

Genea Biomedx (integration with Geri time-lapse incubator)various global IVF clinics/labs

Beyond the preview

Go deeper on AIVF.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIVF.

Explore the full profile